- Home
- LGI vs LUCD Comparison
LGI vs LUCD Comparison
Compare LGI & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | LUCD |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.8M | 183.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LGI | LUCD |
|---|---|---|
| Price | $15.58 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | 51.3K | ★ 595.0K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | N/A | $149.41 |
| Revenue Next Year | N/A | $133.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $13.95 | $0.95 |
| 52 Week High | $19.88 | $1.80 |
Technical Indicators
Market Signals| Indicator | LGI | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 24.22 | 27.01 |
| Support Level | N/A | $1.01 |
| Resistance Level | $17.75 | $1.14 |
| Average True Range (ATR) | 0.45 | 0.07 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 1.82 | 8.19 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.